

# Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

NCT03630055

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Ottawa Heart Institute Research Corporation
<b>Enrollment</b>	1,800 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Willing and able to provide written informed consent
- Age ≥ 18 years
- Diagnostic coronary angiography or percutaneous coronary intervention via the transradial approach

### Exclusion (24)

- Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site
  - Access or attempted access at a second site - including contralateral radial artery, brachial, or femoral artery or vein
  - Planned staged procedure, CABG or noncardiac surgery within 30 days
  - Contraindication or high risk of bleeding with anticoagulation
  - bleeding requiring medical attention in the previous 6 months
- ... and 19 more (see full listing online)

## Locations (3 total)

---

Mayo Clinic, Rochester, Minnesota, United States  
Kingston Health Sciences Center, Kingston, Ontario, Canada  
University of Ottawa Heart Institute, Ottawa, Ontario, Canada